Clinical Trials Logo

Uveitis clinical trials

View clinical trials related to Uveitis.

Filter by:

NCT ID: NCT04340505 Recruiting - Uveitis Clinical Trials

Imaging of Uveitis Patients Receiving Injectable Fluocinolone Acetonide Implant

PANTHER
Start date: August 8, 2019
Phase:
Study type: Observational

We will prospectively observe patients with uveitis who are either active or were recently active in the previous 6 months and are treated with the i-FA implant. All of the patients will have standard clinical exams at baseline and image quantification of their inflammation using OCT, OCTA and UWFFA (if needed). At baseline, ETDRS vision will be measured. Patients will be followed for 12 months months. During follow-up repeat imaging will be performed along with standard examinations, visual acuity and contrast sensitivity measurements. At the final visit, all tests will be repeated. Data collected will be analyzed using statistical software package. Correlations between changes in imaging quantification of inflammation scores and changes in visual acuity, clinical grades of inflammation, and contract sensitivity will be calculated.

NCT ID: NCT04333069 Not yet recruiting - Clinical trials for Cataract; Complicata

Outcome of Cataract Surgery With Uveitis

Start date: April 10, 2020
Phase: N/A
Study type: Interventional

Aim of the study is to evaluate outcome of cataract surgery in different types of uveitis as regarding best corrected visual acuity (BCVA) and rate of post operative complications.

NCT ID: NCT04296838 Terminated - Macular Edema Clinical Trials

Effects of Conbercept in Refractory Uveitic Macular Edema and VEGF

Start date: October 12, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

As a primary exploratory study, this study aims to evaluate the short-term effectiveness of intravitreal Conbercept injection in UME, and to explore the correlation between inflammatory factors like VEGF and the responsiveness to treatment.

NCT ID: NCT04222712 Completed - Clinical trials for Non-infectious Anterior Uveitis

A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis

Start date: February 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study is to evaluate the safety of TRS01 eye drops in participants with active non-infectious anterior uveitis .

NCT ID: NCT04218565 Terminated - Uveitis Clinical Trials

Golimumab for the Treatment of Refractory Behcet's Uveitis

Start date: February 15, 2020
Phase: Phase 2
Study type: Interventional

The aim of this single-center prospective study is to evaluate the efficacy and safety of Golimumab (GOL), fully humanized anti-tumor necrosis factor (TNF)-α monoclonal antibody, in the treatment of refractory Uveitis of Behçet's disease (BDU), to verify its effects on decreasing the dose of cortical steroids, and to determine whether it can reduce BDU recurrence.

NCT ID: NCT04207983 Completed - Clinical trials for Non-infectious Uveitis

A 48 Week Study to Evaluate the Efficacy and Safety of Two (2) EYS606 Treatment Regimens in Subjects With Active Chronic Non-infectious Uveitis (CNIU)

ELECTRO
Start date: February 3, 2020
Phase: Phase 2
Study type: Interventional

The objective of the study is to evaluate the efficacy and safety of two different treatment regimens of EYS606.

NCT ID: NCT04200833 Completed - Clinical trials for JIA Associated Uveitis

Golimumab in Juvenile Idiopathic Arthritis-associated Uveitis Failing Adalimumab

Start date: March 1, 2010
Phase:
Study type: Observational

To asses the use of golimumab, a fully humanized anti-TNF Alpha monoclonal antibody, in juvenile idiopathic Arthritis-associated uveitis refractory to adalimumab.

NCT ID: NCT04193020 Recruiting - Uveitis Clinical Trials

Acute and Chronic Inflammatory Disease, Lifestyle and Treatment Response

ACID LTR
Start date: January 1, 2020
Phase:
Study type: Observational [Patient Registry]

Acute and chronic inflammatory eye diseases are difficult to diagnose and maintain quiescent with therapy. Proposed study is aimed to find on the one hand, novel factors for recurrence of the disease or remission of inflammation and evaluation of the impact of lifestyle and known factors on the other. Each patient is treated in accordance to the best of medical knowledge and guidelines for each disease. This prospective cohort study will enroll uveitic patients to the steroid only group (SG), combined (steroid and adjuvant drug) group (CG) or bilogic therapy group (BTG). At baseline, patient data are recorded using patient-reported outcome measures and clinical assessments (ophthalomology) on disease activity (clinical scales), quality of life, and lifestyle together with registry data on comorbidity and medication. During follow-up evaluation of a successful treatment outcome response will be based on clinical scales and most frequently used primary endpoints; the major outcome of the analyses will be to detect differences in treatment outcome between patients in different treatment group.

NCT ID: NCT04183387 Completed - Uveitis Clinical Trials

Simvastatin in Uveitis

Start date: September 2014
Phase: Phase 2
Study type: Interventional

The study evaluates anti-inflammatory effects and safety of simvastatin in non-infectious uveitis.

NCT ID: NCT04162314 Recruiting - Uveitis Clinical Trials

Beta-1,3/1,6-D-Glucan Ganoderma Lucidum on Non-infectious and Idiopathic Uveitis

Start date: January 21, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

To investigate the effect of Beta-1,3/1,6-D-Glucan from mycelium extract of Indonesian Ganoderma lucidum as an adjuvant to methylprednisolone for non-infectious and idiopathic uveitis